Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;34(7):e302-e303.
doi: 10.1111/jdv.16525. Epub 2020 Jun 4.

Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic

M Kasperkiewicz  1 , E Schmidt  2   3 , J A Fairley  4 , P Joly  5 , A S Payne  6 , M L Yale  7 , D Zillikens  2 , D T Woodley  1
Affiliations

Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic

M Kasperkiewicz et al. J Eur Acad Dermatol Venereol. 2020 Jul.
No abstract available

PubMed Disclaimer

References

    1. Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet 2019; 394: 882–894. - PubMed
    1. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320–332. - PubMed
    1. Russell B, Moss C, George G et al. Associations between immune‐suppressive and stimulating drugs and novel COVID‐19‐a systematic review of current evidence. Ecancermedicalscience 2020; 14: 1022. - PMC - PubMed
    1. Wollenberg A, Flohr C, Simon D et al. European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2)‐infection and atopic dermatitis. J Eur Acad Dermatol Venereol 2020. 10.1111/jdv.16411 - DOI - PubMed
    1. Joly P, Maho‐Vaillant M, Prost‐Squarcioni C et al. First‐line rituximab combined with short‐term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel‐group, open‐label randomised trial. Lancet 2017; 389: 2031–2040. - PubMed

MeSH terms

Substances